CYTK
Price
$38.65
Change
+$0.80 (+2.11%)
Updated
Apr 11 closing price
Capitalization
4.61B
19 days until earnings call
OPT
Price
$3.41
Change
+$0.23 (+7.23%)
Updated
Mar 17 closing price
Capitalization
453.04M
46 days until earnings call
Ad is loading...

CYTK vs OPT

Header iconCYTK vs OPT Comparison
Open Charts CYTK vs OPTBanner chart's image
Cytokinetics
Price$38.65
Change+$0.80 (+2.11%)
Volume$2.45M
Capitalization4.61B
Opthea
Price$3.41
Change+$0.23 (+7.23%)
Volume$3.03K
Capitalization453.04M
CYTK vs OPT Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. OPT commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and OPT is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (CYTK: $38.65 vs. OPT: $3.41)
Brand notoriety: CYTK and OPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 115% vs. OPT: 11%
Market capitalization -- CYTK: $4.61B vs. OPT: $453.04M
CYTK [@Biotechnology] is valued at $4.61B. OPT’s [@Biotechnology] market capitalization is $453.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileOPT’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • OPT’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than OPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while OPT’s TA Score has 2 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 5 bearish.
  • OPT’s TA Score: 2 bullish, 1 bearish.
According to our system of comparison, OPT is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а +3.45% price change this week, while OPT (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

OPT is expected to report earnings on Aug 28, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.61B) has a higher market cap than OPT($453M). OPT YTD gains are higher at: -13.176 vs. CYTK (-17.836). OPT has higher annual earnings (EBITDA): -218.88M vs. CYTK (-493.48M). CYTK has more cash in the bank: 1.08B vs. OPT (132M). OPT has less debt than CYTK: OPT (157M) vs CYTK (789M). CYTK has higher revenues than OPT: CYTK (18.5M) vs OPT (87.7K).
CYTKOPTCYTK / OPT
Capitalization4.61B453M1,017%
EBITDA-493.48M-218.88M225%
Gain YTD-17.836-13.176135%
P/E RatioN/AN/A-
Revenue18.5M87.7K21,095%
Total Cash1.08B132M815%
Total Debt789M157M503%
FUNDAMENTALS RATINGS
CYTK vs OPT: Fundamental Ratings
CYTK
OPT
OUTLOOK RATING
1..100
8227
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
63100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8456
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OPT's Valuation (95) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that OPT’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (63) in the Biotechnology industry is somewhat better than the same rating for OPT (100) in the null industry. This means that CYTK’s stock grew somewhat faster than OPT’s over the last 12 months.

CYTK's SMR Rating (99) in the Biotechnology industry is in the same range as OPT (100) in the null industry. This means that CYTK’s stock grew similarly to OPT’s over the last 12 months.

OPT's Price Growth Rating (56) in the null industry is in the same range as CYTK (84) in the Biotechnology industry. This means that OPT’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for OPT (100) in the null industry. This means that CYTK’s stock grew significantly faster than OPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKOPT
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 27 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 27 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 27 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 27 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
77%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 27 days ago
81%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLSW35.290.97
+2.82%
Franklin FTSE Switzerland ETF
IVEG19.180.51
+2.72%
iShares Emergent Food and AgTch Mult ETF
GOF14.450.26
+1.83%
Guggenheim Strategic Opportunities Fund
PGHY19.14-0.01
-0.08%
Invesco Glb ex-US High Yld Corp Bd ETF
IBTK19.45-0.10
-0.51%
iShares iBonds Dec 2030 Term Trsry ETF

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IDYA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+2.11%
IDYA - CYTK
48%
Loosely correlated
+6.21%
RCKT - CYTK
43%
Loosely correlated
+6.68%
DNLI - CYTK
43%
Loosely correlated
+1.60%
KRON - CYTK
43%
Loosely correlated
+0.30%
DARE - CYTK
42%
Loosely correlated
+1.73%
More